单侧口咽癌IMRT中高位咽后淋巴结豁免的结局
研究纳入102例cN0-N2b单侧口咽癌患者,接受 definitive IMRT(部分联合化疗),对所有患者省略对侧C1椎体水平以上的高位咽后淋巴结预防照射。中位随访26.9个月,全队列及p16+亚组均未出现同侧治疗区或对侧豁免区咽后淋巴结失败,2年咽后失败自由率均为100%。结论认为p16+单侧口咽癌省略对侧高位咽后淋巴结是安全的。
要点
- 单侧口咽癌IMRT中省略对侧C1以上高位咽后淋巴结预防照射,全队列无该区域失败。
- p16+亚组2年总生存率98.0%,咽后失败自由率100%。
- 结论支持p16+单侧口咽癌可安全豁免对侧高位咽后淋巴结照射。
核心结论
- 对p16+单侧口咽癌患者,省略对侧高位咽后淋巴结预防照射是安全的。
研究设计与样本
- 回顾性研究纳入2010至2013年接受根治性IMRT(联合或不联合化疗)的102例cN0-N2b口咽癌患者。
- 所有患者对侧C1椎体水平以上的咽后淋巴结未纳入 elective IMRT 野。
- 67例(66%)有p16状态,其中63例(94%)为p16+。
主要发现
- 中位随访26.9个月(范围3.0-59.9个月),全队列同侧治疗区及对侧豁免高位咽后淋巴结均无失败。
- p16+队列2年总生存率98.0%,局部失败自由率98.1%,区域失败自由率96.4%,远处失败自由率98.1%,咽后失败自由率100%。
- 全队列2年总生存率95.1%,局部失败自由率97.7%,区域失败自由率96.7%,远处失败自由率95.1%,咽后失败自由率100%。
临床怎么用
- 对于p16+单侧口咽癌,IMRT计划可考虑不将对侧C1水平以上高位咽后淋巴结纳入预防照射范围。
局限性
- 研究为回顾性设计,样本量102例,中位随访26.9个月,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The introduction of intensity modulated radiotherapy (IMRT) has facilitated dose painting and sparing of uninvolved/low-risk nodal basins in head and neck cancers. In oropharynx cancer (OPC), the need for elective coverage of uninvolved high contralateral retropharyngeal (RP) nodes and the risk associated with sparing this region remain unclear. We examined outcomes of OPC patients treated with IMRT and omission of contralateral high RP coverage. METHODS AND MATERIALS: We identified 102 OPC patients with cN0-N2b disease treated with definitive IMRT with or without concurrent chemotherapy between 2010 and 2013. The contralateral RP nodal basins superior to the vertebral level of C1 were omitted from the elective IMRT field for all patients. Of the 67 patients (66%) with p16 status available, 63 (94%) were p16+. We used the Kaplan-Meier method to estimate overall survival, as well as freedom from local failure, regional failure, distant failure, and retropharyngeal failure. RESULTS: The median follow-up was 26.9 months (range, 3.0-59.9 months). There were no failures in the treated ipsilateral RP nodes or the spared contralateral high RP nodes in the entire cohort. In the p16+ cohort and the entire cohort, the 2-year rates of overall survival and freedom from local, regional, distant, and retropharyngeal failure were 98.0% and 95.1%, 98.1% and 97.7%, 96.4% and 96.7%, 98.1% and 95.1%, and 100% and 100%, respectively. CONCLUSIONS: Omission of contralateral high RP nodes in patients with p16+ OPC with unilateral disease is safe.
引用
- Leeman JE, Gutiontov S, Romesser P, et al. Sparing of high retropharyngeal nodal basins in patients with unilateral oropharyngeal carcinoma treated with intensity modulated radiation therapy. Pract Radiat Oncol. 2016. PMID: 28094212. doi:10.1016/j.prro.2016.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。